Q32 Bio (QTTB) Accounts Payables (2017 - 2026)
Q32 Bio (QTTB) recorded quarterly Accounts Payables of $653000.0 in Q1 2026, down 25.71% quarter-over-quarter from $879000.0 in Q4 2025, and down 75.92% on a YoY basis from $2.7 million in Q1 2025.
Q32 Bio (QTTB) Accounts Payables (2017 - 2026) Analysis & Trends
Q32 Bio's Accounts Payables history runs 10 years deep, the most recent figure standing at $653000.0 for Q1 2026.
- In Q1 2026, Accounts Payables fell 75.92% year-over-year to $653000.0; the TTM figure through Mar 2026 stood at $653000.0 (down 75.92% YoY), while the FY2025 annual figure was $879000.0, down 70.59% from the prior year.
- Accounts Payables was $653000.0 for Q1 2026 at Q32 Bio, down from $879000.0 in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $9.9 million in Q1 2022 to a low of $653000.0 in Q1 2026.
- Historically, Accounts Payables has averaged $3.3 million across 5 years, with a median of $3.0 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Accounts Payables surged 203.15% in 2023, then sank 83.88% in 2024.
- A 5-year view of Accounts Payables shows it stood at $1.1 million in 2022, then soared by 203.15% to $3.5 million in 2023, then slipped by 13.81% to $3.0 million in 2024, then sank by 70.59% to $879000.0 in 2025, then dropped by 25.71% to $653000.0 in 2026.
- The last three Accounts Payables figures came in at $653000.0 (Q1 2026), $879000.0 (Q4 2025), and $973000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.05 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 83.00 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 8.64 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 489.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 34.55 Mn |
| 10 | Q32 Bio | 167.59 Mn | 116.84 Mn | - | 653,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 653,000.00 |
| Dec 31, 2025 | 879,000.00 |
| Sep 30, 2025 | 973,000.00 |
| Jun 30, 2025 | 910,000.00 |
| Mar 31, 2025 | 2.71 Mn |
| Dec 31, 2024 | 2.99 Mn |
| Sep 30, 2024 | 1.26 Mn |
| Jun 30, 2024 | 2.48 Mn |
| Mar 31, 2024 | 4.96 Mn |
| Dec 31, 2023 | 3.47 Mn |
| Sep 30, 2023 | 7.80 Mn |
| Jun 30, 2023 | 3.39 Mn |
| Mar 31, 2023 | 3.64 Mn |
| Dec 31, 2022 | 1.14 Mn |
| Sep 30, 2022 | 4.84 Mn |
| Jun 30, 2022 | 3.76 Mn |
| Mar 31, 2022 | 9.89 Mn |
| Dec 31, 2021 | 2.37 Mn |
| Sep 30, 2021 | 3.52 Mn |
| Jun 30, 2021 | 5.70 Mn |